Cure developed by VA scientist sells for $1k a pill, out of reach to vets :
A Hepatitis C treatment developed by one of Veterans Affairs' own research scientists is too expensive for the agency to actually use in treating veterans. US lawmakers probing the recent spike in prescription drug prices are furious. Ref. Source 1y.
New study challenges the concept of treatment failure in hepatitis C
New data demonstrate that choosing a different combination of direct-acting antiviral (DAA) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on previous medication regimens. Ref. Source 6b.
Scientists find a way to cure hepatitis C with 6 weeks of treatment
A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a 'short-duration' of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated study demonstrated that the combination of sofosbuvir and ledipasvir for only six weeks is sufficient to treat patients with acute HCV. Ref. Source 5m.
Large global range of prices for hepatitis C medicines raises concerns about affordability
The prices and affordability of recently developed and highly effective direct-acting antivirals for treating hepatitis C vary greatly among countries worldwide, according to a new study. Ref. Source 5z.